Every 8-K that PLUS THERAPEUTICS, Inc. (PSTV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PSTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSTV filings page.
Cerenome, Inc., a CNS oncology company recently rebranded from Plus Therapeutics, reported financial results for the quarter ended June 30, 2026 and provided a business update. The company is advancing its integrated platform combining precision diagnostics, targeted radiotherapeutics and artificial intelligence.
Operationally, Cerenome continued enrollment in its REYOBIQ clinical programs for leptomeningeal metastases and glioblastoma and initiated site activation for the pediatric brain cancer trial, with first dosing expected in the third quarter of 2026. Its CNSide cerebrospinal fluid assay platform performed 232 tests in the first half of 2026 and achieved commercial payer coverage for 150 million covered lives, Medicare identifiers, CAP accreditation for its Houston laboratory, and several data and billing partnerships.
Financially, cash, cash equivalents and investments totaled $8.6 million as of June 30, 2026, unchanged from December 31, 2025. Second-quarter grant revenue was $0.4 million, down from $1.4 million a year earlier. Operating loss widened to $9.1 million from $1.5 million, and the company recorded a net loss of $9.0 million versus net income of $5.2 million in the prior-year quarter.
Cerenome, Inc., formerly Plus Therapeutics, Inc., implemented a corporate name change effective August 3, 2026. A Certificate of Amendment to its Amended and Restated Certificate of Incorporation was filed in Delaware on July 30, 2026 to effect this change.
In connection with the name change, the company’s common stock, par value $0.001 per share, began trading on the Nasdaq Capital Market under the new ticker symbol “CNSY” at the start of trading on August 3, 2026. The company states that there is no change to its CUSIP as a result of the name or trading symbol change, and it has updated its bylaws to reflect the new corporate name.
Plus Therapeutics entered an Equity Distribution Agreement that permits it to sell up to $17,350,000 of common stock through an at-the-market offering with Canaccord Genuity as sales agent.
Shares will be sold from time to time under a Form S-3 shelf registration, with Canaccord earning a 3.0% commission on gross proceeds plus up to $75,000 of reimbursed expenses. Plus Therapeutics can choose when and if to sell, set minimum acceptable prices, and suspend or terminate the program. Net proceeds are intended for general corporate purposes and working capital.
Plus Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved all four proposals presented. The meeting covered director elections, auditor ratification, executive pay and an updated stock incentive plan.
Six directors were elected to terms ending at the 2027 annual meeting, each receiving over 11.8 million votes in favor, with more than 50.8 million broker non-votes recorded. Stockholders ratified CBIZ CPAs, P.C. as independent auditor for 2026 with 60.9 million votes for and 2.3 million against. On an advisory basis, stockholders approved compensation for named executive officers with about 10.4 million votes for and 3.4 million against. They also approved the sixth amendment and restatement of the 2020 Stock Incentive Plan, which received about 8.0 million votes for and 5.6 million against.
Plus Therapeutics reported first quarter 2026 results and updated progress on its REYOBIQ radiotherapeutic and CNSide diagnostics businesses. Grant and diagnostic revenue was $1.0 million, slightly below the prior year, while the company recorded a larger operating loss of $7.1 million as it expanded R&D and commercial activities.
Net loss narrowed to $6.9 million, or $1.05 per share, compared with a $17.4 million loss, or $29.86 per share, a year earlier, largely due to the absence of prior-period noncash derivative and financing charges. Cash, cash equivalents, and investments rose to $15.1 million as of March 31, 2026, helped by a $15 million upsized public equity offering completed in January.
Operationally, the company advanced its central nervous system oncology platform by securing FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, obtaining new reimbursement codes for REYOBIQ delivery and CNSide, adding a second GMP manufacturing site, and expanding payer coverage for CNSide to about 81 million covered lives while scaling commercial infrastructure.
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company has regained compliance with the exchange’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq found that, from April 6 to April 17, 2026, the closing bid price of the company’s common stock was at or above $1.00 per share.
This followed a one-for-twenty-five reverse split of the company’s common stock, which became effective on April 2, 2026. The company issued a press release on April 21, 2026 announcing the compliance confirmation and noting that Nasdaq has advised the matter is now closed.
Plus Therapeutics, Inc. appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. He will oversee development and approval of the company’s pharmaceutical pipeline.
Under his employment agreement, Dr. Daniels will receive a $460,000 base salary, a 40% target bonus, 20,000 stock options and 20,000 restricted stock units, along with severance and partial equity vesting acceleration if he is terminated without cause or resigns for good reason.
Plus Therapeutics reported that the U.S. FDA has granted Orphan Drug Designation to its radiotherapeutic candidate REYOBIQ (rhenium Re186 obisbemeda) for treating pediatric malignant gliomas, a group of rare, aggressive brain tumors with limited options and poor outcomes.
The designation, which also encompasses pediatric ependymoma, offers potential benefits such as seven years of market exclusivity upon approval, tax credits for clinical trial costs, and certain fee exemptions. It builds on prior regulatory and clinical progress for REYOBIQ in leptomeningeal metastases and pediatric brain cancers, where the drug is being studied in multiple ongoing ReSPECT trials.
Plus Therapeutics, Inc. has implemented a 1-for-25 reverse stock split of its common stock to help meet the Nasdaq Capital Market’s minimum $1.00 bid price requirement for continued listing. The split became effective at 12:01 a.m. Eastern time on April 2, 2026.
Every 25 pre-split shares were combined into one share, reducing issued and outstanding common stock from approximately 171,550,698 shares to approximately 6,862,027 shares, with no change to par value or voting rights. No fractional shares will be issued; eligible holders will receive cash in lieu of fractions. Outstanding equity awards and warrants, as well as shares reserved under the equity plan, are being adjusted proportionately. The stock continues to trade on Nasdaq under the symbol PSTV with a new CUSIP number 72941H806.
Plus Therapeutics announced a board change, appointing Ronald A. Andrews as a director effective March 20, 2026, to fill the vacancy created by the resignation of Dr. Robert Lenk. The board also determined that Andrews qualifies as an independent director under Nasdaq rules and named him to the Nominating and Corporate Governance Committee.
Andrews brings more than 35 years of leadership experience in diagnostics and molecular diagnostics, including prior CEO roles and multiple board positions. He will receive standard non-employee director compensation and is expected to sign the company’s standard director indemnification agreement. Dr. Lenk’s resignation was not due to any disagreement regarding the company’s operations, policies, or practices.
Plus Therapeutics, Inc. plans to hold its 2026 Annual Meeting of Stockholders on May 14, 2026, at 9:00 a.m. Eastern Time, as a virtual-only meeting by remote communication. Stockholders of record at the close of business on March 18, 2026 are currently expected to be entitled to vote.
The company set new deadlines because the 2026 meeting date is more than 30 days before the prior year’s meeting. Stockholder proposals under Rule 14a-8 and advance-notice bylaw nominations or other business must be received by the Corporate Secretary by March 22, 2026, including notices required under the universal proxy rules.
Plus Therapeutics reported 2025 results that combine larger losses with a much stronger balance sheet and strategic progress in CNS cancer programs. Grant revenue was $5.2 million for the year, while net loss widened to $22.4 million, or $(0.29) per basic share, compared with a $13.0 million loss in 2024.
Cash, cash equivalents and investments rose to $13.1 million as of December 31, 2025, up from $3.6 million a year earlier, helped by an upsized public offering that generated $15 million in gross proceeds and additional equity sales. The company is prioritizing CNSide commercial scale-up and pivotal trial readiness for its REYOBIQ radiotherapeutic.
Operationally, Plus Therapeutics secured an AMA Category III CPT code for REYOBIQ delivery, expanded CNSide laboratory licensing to 49 U.S. states, and added national coverage agreements that extend CNSide test policy coverage to about 67 million people. For 2026, it targets key REYOBIQ clinical milestones, expanded payer coverage to more than 150 million covered lives, and CNSide Diagnostics breakeven by 2027.
Plus Therapeutics updated its executive pay disclosure by adding 2025 discretionary cash bonuses for its named executive officers. The Compensation Committee approved these bonuses on February 9, 2026, completing the previously incomplete 2025–2024 summary compensation table originally referenced in a Form S-1 registration statement.
For 2025, President and CEO Marc H. Hedrick, M.D. received total compensation of $5,566,732, including a $585,000 salary, option awards valued at $3,531,841, restricted stock awards of $1,100,647, non-equity incentive plan compensation of $305,663, and other compensation of $43,581. Chief Financial Officer Andrew Sims received 2025 total compensation of $1,631,279, including a $390,000 salary, option awards of $810,388, restricted stock awards of $264,154, non-equity incentive plan compensation of $149,175, and other compensation of $17,562. Former Chief Medical Officer Norman LaFrance, M.D., who stepped down on June 11, 2024, shows no 2025 compensation, with 2024 total compensation of $285,912.
Plus Therapeutics, Inc. filed a current report noting that it has updated its corporate investor presentation for use in meetings with investors, analysts, and other stakeholders. The updated materials are provided as an exhibit labeled an investor presentation as of January 22, 2026.
The company indicates that these slides are intended to support discussions about its business with the financial community and others by providing a refreshed overview in a single document.
Plus Therapeutics, Inc. completed an underwritten public offering of 39,473,684 shares of common stock and 39,473,684 warrants at a combined public offering price of $0.38 per share and warrant, generating approximately $13.3 million in net proceeds after underwriting discounts, commissions and expenses. The company also granted the underwriter a 30-day option to buy up to an additional 5,921,052 shares, additional warrants to purchase up to 5,921,052 shares, or a combination, and the underwriter exercised this option for additional warrants to purchase 5,921,052 shares. Each warrant is immediately exercisable at $0.38 per share and expires five years from issuance, and the company expects to use the net proceeds for working capital and general corporate purposes. The company and its directors and executive officers agreed to 45-day lock-up restrictions, and the company agreed to avoid variable rate transactions for 120 days after the final prospectus date.
Plus Therapeutics, Inc. (PSTV) announced that Nasdaq has granted the company an additional 180-day period, until May 11, 2026, to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The prior deadline had been November 12, 2025, after the stock traded below $1.00 for 30 consecutive business days as of May 16, 2025.
The company plans to continue monitoring its share price and has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its common stock to attempt to restore compliance. If compliance is not regained within the extended period, Nasdaq may commence delisting of the common stock, which the company would have the right to appeal. There is no assurance that Plus Therapeutics will regain or maintain compliance with Nasdaq listing standards.
Plus Therapeutics (PSTV) filed an 8-K stating it reported financial results for the third quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1, which is incorporated by reference.
The disclosure under Item 2.02 is furnished, not filed, under the Exchange Act. This routine update provides access to the company’s Q3 2025 results through the attached press release.
Plus Therapeutics (PSTV) disclosed a new long-term facility lease in Houston. The company agreed to lease approximately 11,370 rentable square feet at 6420 Levit Green Boulevard, with the lease expected to commence on or about November 1, 2026. The initial term is 120 calendar months.
Monthly base rent starts at $58,745 and increases annually by approximately 3%, plus the company’s share of the building’s direct expenses. This creates a multi-year operating commitment tied to growth and operational needs at the Houston site.
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company is back in compliance with two key continued listing standards. Nasdaq determined that Plus Therapeutics meets the Market Value of Listed Securities standard, which requires a market value of at least $35 million, and the stockholders’ equity standard, which requires equity of at least $2.5 million. As a result, the company now satisfies two alternative criteria under Nasdaq Listing Rule 5550.
Because of this, Nasdaq has allowed Plus Therapeutics to use the remainder of its grace period to fix its continued deficiency under the $1.00 bid price rule, extending the deadline to November 12, 2025 instead of the earlier September 8, 2025 date. However, the company’s compliance with the equity requirement is subject to a one-year monitoring period through August 22, 2026. If it falls out of compliance with the equity standard and does not meet another alternative standard during that period, Nasdaq staff would issue a delisting determination, and the company’s only recourse would be to request a new hearing.
Plus Therapeutics reported that Nasdaq's Listing Qualifications Department found it did not meet the minimum stockholders' equity requirement after the company reported a stockholders' deficit of ($23,641,000) for the period ended March 31, 2025. The Staff initially determined to delist the company's securities, and the company timely requested a hearing.
A Nasdaq Hearings Panel granted continued listing subject to two conditions: demonstrate compliance with the $2.5 million equity requirement by August 14, 2025 through a public filing describing transactions and indicating post-transaction equity (optionally including a balance sheet not older than 60 days with pro forma adjustments), and have the closing bid price meet or exceed $1.00 per share for 10 consecutive business days by September 8, 2025.
Plus Therapeutics reported the results of its August 7, 2025 annual meeting. Of 60,490,101 shares outstanding at the June 18, 2025 record date, 29,973,272 shares were represented, constituting a quorum. All director nominees listed in the proxy were elected, with individual "for" votes generally in the range of 18.7 million to 18.94 million and 10,294,600 broker non-votes recorded for those director elections.
Stockholders approved several material proposals: authorization to potentially issue up to $50.0 million of common stock (plus up to $1.0 million as a commitment fee) to Lincoln Park Capital under the June 17, 2025 purchase agreement; discretionary authority for the board to effect a reverse stock split at any ratio between 1-for-2 and 1-for-250; an advisory approval of named executive officer compensation; and the fifth amendment and restatement of the 2020 Stock Incentive Plan.
Plus Therapeutics has entered into a significant $50 million purchase agreement with Lincoln Park Capital Fund on June 17, 2025. The 36-month agreement allows Plus to sell common stock to Lincoln Park at its discretion, subject to specific conditions.
Key terms include:
- Regular purchases up to 300,000 shares (increasable to 500,000 shares based on stock price)
- Purchase price set at 97% of the lower of current sale price or 3-day average
- Additional "Accelerated Purchase" options available up to 300% of regular purchase amount
- Exchange Cap limitation of 10,194,593 shares (19.99% of outstanding shares) unless certain price conditions are met
Notably, Plus has agreed to use 90% of proceeds after July 1, 2025, for a $17.3 million Make-Whole Repayment to certain warrant holders. Lincoln Park will receive a $500,000 initial commitment fee and potential additional $500,000 fee if sales exceed $25 million.